ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,615.35
      0.55%
      US Tech 100
      19,804.00
      0.64%
      Dow Jones
      40,000.90
      0.62%
      Brent Oil
      84.57
      0.00%
      Bitcoin
      58,662.94
      1.33%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Kazia Therapeutics Ltd (KZIA)

      7. Kazia Therapeutics Ltd (KZIA) News

      KZIA

      Kazia Therapeutics (KZIA)

      Kazia Therapeutics Ltd
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:KZIA
      DateTimeSourceHeadlineSymbolCompany
      09/09/20228:00AMPR Newswire (US)KAZIA THERAPEUTICS TO PRESENT AT HC WAINWRIGHT 24th ANNUAL GLOBAL INVESTMENT CONFERENCENASDAQ:KZIAKazia Therapeutics Ltd
      09/08/20225:07PMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:KZIAKazia Therapeutics Ltd
      09/08/20228:30AMPR Newswire (US)KAZIA TO PRESENT FINAL DATA FROM PAXALISIB PHASE II STUDY IN GLIOBLASTOMA AT ESMONASDAQ:KZIAKazia Therapeutics Ltd
      09/01/20224:10PMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:KZIAKazia Therapeutics Ltd
      08/05/20228:46AMPR Newswire (US)KAZIA THERAPEUTICS REPORTS PROMISING INTERIM DATA FROM COMBINATION STUDY OF PAXALISIB WITH RADIOTHERAPY IN TREATMENT OF BRAIN METASTASESNASDAQ:KZIAKazia Therapeutics Ltd
      08/05/20228:40AMPR Newswire (US)KAZIA THERAPEUTICS REPORTS PROMISING INTERIM DATA FROM COMBINATION STUDY OF PAXALISIB WITH RADIOTHERAPY IN TREATMENT OF BRAIN METASTASESNASDAQ:KZIAKazia Therapeutics Ltd
      08/05/20228:19AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:KZIAKazia Therapeutics Ltd
      08/01/20228:52AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:KZIAKazia Therapeutics Ltd
      07/12/20228:15AMPR Newswire (US)KAZIA LAUNCHES NEW SCIENTIFIC ADVISORY BOARD COMPRISED OF WORLD-LEADING EXPERTS IN BRAIN CANCERNASDAQ:KZIAKazia Therapeutics Ltd
      07/06/20227:00AMPR Newswire (US)US FDA AWARDS RARE PEDIATRIC DISEASE DESIGNATION (RPDD) TO PAXALISIB FOR AT/RT, A RARE FORM OF CHILDHOOD BRAIN CANCERNASDAQ:KZIAKazia Therapeutics Ltd
      07/06/20226:05AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:KZIAKazia Therapeutics Ltd
      06/30/20226:06AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:KZIAKazia Therapeutics Ltd
      06/23/20227:41AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:KZIAKazia Therapeutics Ltd
      06/17/20224:55PMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:KZIAKazia Therapeutics Ltd
      06/17/20228:00AMPR Newswire (US)US FDA AWARDS ORPHAN DRUG DESIGNATION (ODD) TO PAXALISIB FOR AT/RT, A RARE FORM OF CHILDHOOD BRAIN CANCERNASDAQ:KZIAKazia Therapeutics Ltd
      06/13/20227:00AMPR Newswire (US)POSITIVE DATA FOR PAXALISIB IN TWO CHILDHOOD BRAIN CANCERS PRESENTED AT 20TH ISPNO ANNUAL MEETINGNASDAQ:KZIAKazia Therapeutics Ltd
      06/08/202212:45PMTipRanksAnalysts Offer Insights on Healthcare Companies: Incyte (INCY) and Kazia Therapeutics (KZIA)NASDAQ:KZIAKazia Therapeutics Ltd
      06/07/20227:00AMPR Newswire (US)PHASE II STUDY OF PAXALISIB IN BRAIN METASTASES ADVANCES TO EXPANSION STAGE IN BREAST CANCER BRAIN METASTASES COHORTNASDAQ:KZIAKazia Therapeutics Ltd
      06/03/20227:00AMPR Newswire (US)KAZIA PRESENTS POSITIVE FINAL DATA FROM PHASE II STUDY OF PAXALISIB IN NEWLY DIAGNOSED GLIOBLASTOMA AT ASCO CONFERENCENASDAQ:KZIAKazia Therapeutics Ltd
      05/31/20227:20AMPR Newswire (US)GBM AGILE OPENS TO PAXALISIB IN EUROPENASDAQ:KZIAKazia Therapeutics Ltd
      05/23/20228:30AMPR Newswire (US)KAZIA THERAPEUTICS TO PRESENT AT UPCOMING INVESTOR CONFERENCES HOSTED BY HC WAINWRIGHT AND LD MICRONASDAQ:KZIAKazia Therapeutics Ltd
      05/17/20228:00AMPR Newswire (US)KAZIA MARKS DIPG AWARENESS DAY; NEW PRECLINICAL DATA IN DIPG TO BE PRESENTED AT ISPNO CONFERENCENASDAQ:KZIAKazia Therapeutics Ltd
      04/29/202211:00AMPR Newswire (US)KAZIA TO PRESENT FINAL DATA FROM PAXALISIB PHASE II STUDY IN GLIOBLASTOMA AT ASCONASDAQ:KZIAKazia Therapeutics Ltd
      04/22/20224:07PMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:KZIAKazia Therapeutics Ltd
      04/22/20224:05PMEdgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:KZIAKazia Therapeutics Ltd
      04/08/20228:30AMPR Newswire (US)KAZIA THERAPEUTICS ANNOUNCES PRECLINICAL DATA PRESENTED AT AACR CONFERENCE BY JOHNS HOPKINS UNIVERSITY SHOWING ACTIVITY OF PAXALISIB IN PAEDIATRIC BRAIN TUMOURSNASDAQ:KZIAKazia Therapeutics Ltd
      04/08/20228:00AMPR Newswire (US)TWO ABSTRACTS AT AACR CONFERENCE PRESENT DETAILED STUDY DESIGN AND INNOVATIVE BIOMARKER STRATEGY FOR ONGOING PHASE I STUDY OF EVT801 IN ADVANCED CANCERNASDAQ:KZIAKazia Therapeutics Ltd
      03/24/20226:07AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:KZIAKazia Therapeutics Ltd
      03/21/20228:00AMPR Newswire (US)KAZIA TO PRESENT AT UPCOMING INVESTOR CONFERENCE AND AACR ANNUAL SCIENTIFIC MEETINGNASDAQ:KZIAKazia Therapeutics Ltd
      02/28/20228:00AMPR Newswire (US)PHASE II CLINICAL STUDY AT WEILL CORNELL MEDICAL CENTER INVESTIGATING PAXALISIB IN COMBINATION WITH METFORMIN AND A KETOGENIC DIET ENROLLS FIRST PATIENTNASDAQ:KZIAKazia Therapeutics Ltd
       Showing the most relevant articles for your search:NASDAQ:KZIA

      Your Recent History

      BIT
      S32116
      Societe Generale Effekten
      Delayed Upgrade Clock